| Name | Title | Contact Details |
|---|
Alere is committed to delivering high performance diagnostics that meet growing global demand for accurate, easy-to-use and cost-effective tests. The Alere i molecular platform, for example, delivers lab-quality results for Influenza A&B in less than 15 minutes.
Eclipse Salon is a Cortez, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HonorHealth is both a name and call to action. HonorHealth emphasizes the historic trustworthiness and integrity of our organization`s brand. It demonstrates our respect and dedication to delivering the highest quality care in a personal and easy manner. We are committed to providing the right care at the right time at the right place. We continue to engage our communities in wellness. We make it easier than ever for you to get the personalized care you need in a way that works for you. With more than 3,000 expert physicians, 10,000 dedicated employees, and 3,000 caring volunteers, HonorHealth continues to strengthen our communities, making sure that everyone has access to quality healthcare.
Osler Health is on the vanguard of medical providers making the transition from being service providers to clinical managers. That means we are also responsible for the totality of each patients care. Osler Health is committed to providing the right care, at the right time, and, at the right cost to deliver the best results. That is why we do not partner with hospitals so that we are rewarded for your good health, not when you lose it. Osler is ranked in the top 10% nationally for quality, and 100% of our practices use advanced technology. Osler patients are also 112% healthier relative to peer groups. Our Mission – To improve the health status of each patient efficiently, effectively and with the highest quality care. Our Vision – To transform healthcare from a Managing Sickness model to a Preserving Wellness model.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."